Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.
Identifieur interne : 003120 ( Main/Exploration ); précédent : 003119; suivant : 003121Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.
Auteurs : Weiwei Gai [République populaire de Chine] ; Wei Zou ; Lei Lei ; Junyi Luo ; Haobo Tu ; Yan Zhang ; Kai Wang ; Po Tien ; Huimin YanSource :
- Viral immunology [ 0882-8245 ] ; 2008.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Administration par voie nasale, Animaux, Anticorps antiviraux (sang), Femelle, Immunoglobuline A (analyse), Immunoglobuline G (sang), Injections péritoneales, Muqueuse intestinale (immunologie), Oligodésoxyribonucléotides (administration et posologie), Oligodésoxyribonucléotides (pharmacologie), Poumon (immunologie), Salive (immunologie), Souris, Système génital (immunologie), Sérum (immunologie), Tests de neutralisation, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Oligodésoxyribonucléotides, Vaccins antiviraux, Vaccins inactivés.
- analyse : Immunoglobuline A.
- immunologie : Muqueuse intestinale, Poumon, Salive, Système génital, Sérum, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS.
- pharmacologie : Oligodésoxyribonucléotides.
- sang : Anticorps antiviraux, Immunoglobuline G.
- Administration par voie nasale, Animaux, Femelle, Injections péritoneales, Souris, Tests de neutralisation.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Administration, Intranasal, Animals, Antibodies, Viral (blood), Female, Genitalia (immunology), Immunoglobulin A (analysis), Immunoglobulin G (blood), Injections, Intraperitoneal, Intestinal Mucosa (immunology), Lung (immunology), Mice, Neutralization Tests, Oligodeoxyribonucleotides (administration & dosage), Oligodeoxyribonucleotides (pharmacology), SARS Virus (immunology), Saliva (immunology), Serum (immunology), Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Oligodeoxyribonucleotides, Vaccines, Inactivated, Viral Vaccines.
- chemical , analysis : Immunoglobulin A.
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- immunology : Genitalia, Intestinal Mucosa, Lung, SARS Virus, Saliva, Serum, Vaccines, Inactivated, Viral Vaccines.
- chemical , pharmacology : Oligodeoxyribonucleotides.
- Administration, Intranasal, Animals, Female, Injections, Intraperitoneal, Mice, Neutralization Tests.
Abstract
Severe acute respiratory syndrome (SARS) is a deadly and highly infectious disease caused by SARS Coronavirus (SARS-CoV). Inactivated SARS-CoV has been explored as a vaccine against SARS-CoV; however, current knowledge of inactivated SARS-CoV vaccine is quite limited. We attempted to investigate the effects of different immunization protocols and adjuvant on the antibody responses to inactivated SARS-CoV vaccine. With an intraperitoneal (IP) immunization protocol, inactivated SARS-CoV alone induced significant amounts of SARS-CoV-specific IgG antibodies in sera and a small quantity of SARS-CoV-specific IgA antibodies in the genital tract and feces, but failed to induce any detectable SARS-CoV-specific IgA antibodies in sera, saliva, lung, and intestine, and the addition of CpG ODN 2006 had only a marginal effect on antibody production. In contrast, with an intranasal (IN) immunization protocol, inactivated SARS-CoV alone failed to induce any detectable SARS-CoV-specific IgA antibodies in sera, saliva, lung, and intestine, except for a small quantity of IgA antibodies in fecal extracts and the genital tract, along with IgG antibodies in sera, but when given with adjuvant CpG ODN 2006, inactivated SARS-CoV induced significant amounts of SARS-CoV-specific IgG antibodies in sera, and a detectable amount of SARS-CoV-specific IgA antibodies in sera and all tested mucosal secretions and tissues (i.e., saliva, the genital tract, fecal extract, lung, and intestine). On a neutralization assay, neutralizing activity with the IP immunization protocol was detected in sera and mucosal secretions (from the saliva and genital tract), but sera from the IN protocol failed to show any neutralizing activity. Our study demonstrated that inactivated SARS-CoV vaccine is promising, and our data provide a sound foundation for the development of an effective inactivated SARS-CoV vaccine.
DOI: 10.1089/vim.2007.0079
PubMed: 18355120
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001B87
- to stream PubMed, to step Curation: 001B87
- to stream PubMed, to step Checkpoint: 001B43
- to stream Ncbi, to step Merge: 001C05
- to stream Ncbi, to step Curation: 001C05
- to stream Ncbi, to step Checkpoint: 001C05
- to stream Main, to step Merge: 003210
- to stream Main, to step Curation: 003120
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.</title><author><name sortKey="Gai, Weiwei" sort="Gai, Weiwei" uniqKey="Gai W" first="Weiwei" last="Gai">Weiwei Gai</name><affiliation wicri:level="4"><nlm:affiliation>The State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan University, Wuhan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan University, Wuhan</wicri:regionArea><placeName><settlement type="city">Wuhan</settlement><region type="région">Hubei</region></placeName><orgName type="university">Université de Wuhan</orgName></affiliation></author><author><name sortKey="Zou, Wei" sort="Zou, Wei" uniqKey="Zou W" first="Wei" last="Zou">Wei Zou</name></author><author><name sortKey="Lei, Lei" sort="Lei, Lei" uniqKey="Lei L" first="Lei" last="Lei">Lei Lei</name></author><author><name sortKey="Luo, Junyi" sort="Luo, Junyi" uniqKey="Luo J" first="Junyi" last="Luo">Junyi Luo</name></author><author><name sortKey="Tu, Haobo" sort="Tu, Haobo" uniqKey="Tu H" first="Haobo" last="Tu">Haobo Tu</name></author><author><name sortKey="Zhang, Yan" sort="Zhang, Yan" uniqKey="Zhang Y" first="Yan" last="Zhang">Yan Zhang</name></author><author><name sortKey="Wang, Kai" sort="Wang, Kai" uniqKey="Wang K" first="Kai" last="Wang">Kai Wang</name></author><author><name sortKey="Tien, Po" sort="Tien, Po" uniqKey="Tien P" first="Po" last="Tien">Po Tien</name></author><author><name sortKey="Yan, Huimin" sort="Yan, Huimin" uniqKey="Yan H" first="Huimin" last="Yan">Huimin Yan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18355120</idno><idno type="pmid">18355120</idno><idno type="doi">10.1089/vim.2007.0079</idno><idno type="wicri:Area/PubMed/Corpus">001B87</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B87</idno><idno type="wicri:Area/PubMed/Curation">001B87</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B87</idno><idno type="wicri:Area/PubMed/Checkpoint">001B43</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B43</idno><idno type="wicri:Area/Ncbi/Merge">001C05</idno><idno type="wicri:Area/Ncbi/Curation">001C05</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C05</idno><idno type="wicri:doubleKey">0882-8245:2008:Gai W:effects:of:different</idno><idno type="wicri:Area/Main/Merge">003210</idno><idno type="wicri:Area/Main/Curation">003120</idno><idno type="wicri:Area/Main/Exploration">003120</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.</title><author><name sortKey="Gai, Weiwei" sort="Gai, Weiwei" uniqKey="Gai W" first="Weiwei" last="Gai">Weiwei Gai</name><affiliation wicri:level="4"><nlm:affiliation>The State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan University, Wuhan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan University, Wuhan</wicri:regionArea><placeName><settlement type="city">Wuhan</settlement><region type="région">Hubei</region></placeName><orgName type="university">Université de Wuhan</orgName></affiliation></author><author><name sortKey="Zou, Wei" sort="Zou, Wei" uniqKey="Zou W" first="Wei" last="Zou">Wei Zou</name></author><author><name sortKey="Lei, Lei" sort="Lei, Lei" uniqKey="Lei L" first="Lei" last="Lei">Lei Lei</name></author><author><name sortKey="Luo, Junyi" sort="Luo, Junyi" uniqKey="Luo J" first="Junyi" last="Luo">Junyi Luo</name></author><author><name sortKey="Tu, Haobo" sort="Tu, Haobo" uniqKey="Tu H" first="Haobo" last="Tu">Haobo Tu</name></author><author><name sortKey="Zhang, Yan" sort="Zhang, Yan" uniqKey="Zhang Y" first="Yan" last="Zhang">Yan Zhang</name></author><author><name sortKey="Wang, Kai" sort="Wang, Kai" uniqKey="Wang K" first="Kai" last="Wang">Kai Wang</name></author><author><name sortKey="Tien, Po" sort="Tien, Po" uniqKey="Tien P" first="Po" last="Tien">Po Tien</name></author><author><name sortKey="Yan, Huimin" sort="Yan, Huimin" uniqKey="Yan H" first="Huimin" last="Yan">Huimin Yan</name></author></analytic><series><title level="j">Viral immunology</title><idno type="ISSN">0882-8245</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Female</term><term>Genitalia (immunology)</term><term>Immunoglobulin A (analysis)</term><term>Immunoglobulin G (blood)</term><term>Injections, Intraperitoneal</term><term>Intestinal Mucosa (immunology)</term><term>Lung (immunology)</term><term>Mice</term><term>Neutralization Tests</term><term>Oligodeoxyribonucleotides (administration & dosage)</term><term>Oligodeoxyribonucleotides (pharmacology)</term><term>SARS Virus (immunology)</term><term>Saliva (immunology)</term><term>Serum (immunology)</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Administration par voie nasale</term><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Femelle</term><term>Immunoglobuline A (analyse)</term><term>Immunoglobuline G (sang)</term><term>Injections péritoneales</term><term>Muqueuse intestinale (immunologie)</term><term>Oligodésoxyribonucléotides (administration et posologie)</term><term>Oligodésoxyribonucléotides (pharmacologie)</term><term>Poumon (immunologie)</term><term>Salive (immunologie)</term><term>Souris</term><term>Système génital (immunologie)</term><term>Sérum (immunologie)</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés (administration et posologie)</term><term>Vaccins inactivés (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Oligodeoxyribonucleotides</term><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Immunoglobulin A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Oligodésoxyribonucléotides</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Immunoglobuline A</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Muqueuse intestinale</term><term>Poumon</term><term>Salive</term><term>Système génital</term><term>Sérum</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Genitalia</term><term>Intestinal Mucosa</term><term>Lung</term><term>SARS Virus</term><term>Saliva</term><term>Serum</term><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Oligodésoxyribonucléotides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oligodeoxyribonucleotides</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Female</term><term>Injections, Intraperitoneal</term><term>Mice</term><term>Neutralization Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Femelle</term><term>Injections péritoneales</term><term>Souris</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a deadly and highly infectious disease caused by SARS Coronavirus (SARS-CoV). Inactivated SARS-CoV has been explored as a vaccine against SARS-CoV; however, current knowledge of inactivated SARS-CoV vaccine is quite limited. We attempted to investigate the effects of different immunization protocols and adjuvant on the antibody responses to inactivated SARS-CoV vaccine. With an intraperitoneal (IP) immunization protocol, inactivated SARS-CoV alone induced significant amounts of SARS-CoV-specific IgG antibodies in sera and a small quantity of SARS-CoV-specific IgA antibodies in the genital tract and feces, but failed to induce any detectable SARS-CoV-specific IgA antibodies in sera, saliva, lung, and intestine, and the addition of CpG ODN 2006 had only a marginal effect on antibody production. In contrast, with an intranasal (IN) immunization protocol, inactivated SARS-CoV alone failed to induce any detectable SARS-CoV-specific IgA antibodies in sera, saliva, lung, and intestine, except for a small quantity of IgA antibodies in fecal extracts and the genital tract, along with IgG antibodies in sera, but when given with adjuvant CpG ODN 2006, inactivated SARS-CoV induced significant amounts of SARS-CoV-specific IgG antibodies in sera, and a detectable amount of SARS-CoV-specific IgA antibodies in sera and all tested mucosal secretions and tissues (i.e., saliva, the genital tract, fecal extract, lung, and intestine). On a neutralization assay, neutralizing activity with the IP immunization protocol was detected in sera and mucosal secretions (from the saliva and genital tract), but sera from the IN protocol failed to show any neutralizing activity. Our study demonstrated that inactivated SARS-CoV vaccine is promising, and our data provide a sound foundation for the development of an effective inactivated SARS-CoV vaccine.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Hubei</li></region><settlement><li>Wuhan</li></settlement><orgName><li>Université de Wuhan</li></orgName></list><tree><noCountry><name sortKey="Lei, Lei" sort="Lei, Lei" uniqKey="Lei L" first="Lei" last="Lei">Lei Lei</name><name sortKey="Luo, Junyi" sort="Luo, Junyi" uniqKey="Luo J" first="Junyi" last="Luo">Junyi Luo</name><name sortKey="Tien, Po" sort="Tien, Po" uniqKey="Tien P" first="Po" last="Tien">Po Tien</name><name sortKey="Tu, Haobo" sort="Tu, Haobo" uniqKey="Tu H" first="Haobo" last="Tu">Haobo Tu</name><name sortKey="Wang, Kai" sort="Wang, Kai" uniqKey="Wang K" first="Kai" last="Wang">Kai Wang</name><name sortKey="Yan, Huimin" sort="Yan, Huimin" uniqKey="Yan H" first="Huimin" last="Yan">Huimin Yan</name><name sortKey="Zhang, Yan" sort="Zhang, Yan" uniqKey="Zhang Y" first="Yan" last="Zhang">Yan Zhang</name><name sortKey="Zou, Wei" sort="Zou, Wei" uniqKey="Zou W" first="Wei" last="Zou">Wei Zou</name></noCountry><country name="République populaire de Chine"><region name="Hubei"><name sortKey="Gai, Weiwei" sort="Gai, Weiwei" uniqKey="Gai W" first="Weiwei" last="Gai">Weiwei Gai</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003120 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003120 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18355120
|texte= Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18355120" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |